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CLARKE D. FORSYTHE & DONNA HARRISON, M.D.

State Regulation of Chemical Abortion After Dobbs
ABSTRACT
Roe v. Wade legalized abortion in all 50 states for any reason, at any time
of pregnancy, and thereby paved the way for the development of new
abortifacients. Chemical abortion, also referred to as RU-486, is a two-drug
regimen. The first, mifepristone (brand name, Mifeprex), is an
antiprogesterone, which starves the pregnancy. The second, misoprostol
(brand name, Cytotec), a prostaglandin, causes the uterus to contract, which
mechanically expels the fetus and placenta. The United States Food & Drug
Administration (FDA) approved chemical abortion for the U.S. medical
market in September 2000 and, since then, it has steadily and significantly
increased as a percentage of all abortions.
Abortion advocates are now prioritizing chemical abortion to replace
surgical abortion, which necessarily involves doctors, in order to demedicalize abortion and exclude doctors entirely. The inherent risks of
mifepristone and misoprostol include incomplete abortion, septic infection,
and excessive hemorrhage. The inherent risks, combined with lax federal
protection of women’s health and a U.S. healthcare system that does not
reliably track abortions or their complications, demonstrate that the states
have compelling interests within their traditional police powers to protect
women’s health by prohibiting or regulating chemical abortion. The active
promotion and proliferation of chemical abortion will be a significant
challenge for state officials who wish to protect women’s health and prenatal
human beings after Dobbs.
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ARTICLE
STATE REGULATION OF CHEMICAL ABORTION AFTER DOBBS
Clarke D. Forsythe† & Donna Harrison, M.D.††
I. INTRODUCTION
Stories about pessaries, potions, herbs, or chemicals to attempt abortion,
whether effective or not, have a long social and legal history.1 Since the U.S.
Food and Drug Administration (FDA) approved RU-486 for the medical
marketplace in September 2000,2 chemical or drug-induced abortion has
reportedly become a greater percentage of all abortions in the United States.3
Although named RU-486 by the French pharmaceutical company Roussel
Uclaf, the FDA approved it in the U.S. as a two-drug regimen involving
mifepristone (brand name, Mifeprex) and misoprostol (brand name,
Cytotec).4 Abortion advocates have long promoted a shift from surgical to
†

Senior Counsel, Americans United for Life. We are grateful to Ryan Desrosiers, Hugh
Phillips, and Carolyn McDonnell, Esq. for excellent research assistance, to Regina Maitlen,
Esq. for her review, and to Katie Glenn, Esq. for inspiration and encouragement. We thank
Christopher Horton and numerous editors and staff of the Liberty University Law Review
for their excellent work which improved the manuscript.
††
M.D. (University of Michigan). Dr. Harrison is a diplomate of the American Board of
Obstetrics and Gynecology. She is currently CEO of the American Association of Pro-Life
Obstetricians and Gynecologists (AAPLOG). Dr. Harrison was a co-author of the 2002
Citizen Petition cited herein and filed by AAPLOG.
1
JOSEPH W. DELLAPENNA, DISPELLING THE MYTHS OF ABORTION HISTORY 37–51 (2006).
2
Mifeprex (mifepristone) Information (Dec. 16, 2021), FDA,
https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-andproviders/mifeprex-mifepristone-information.
3
See Katherine Kortsmit et al., Abortion Surveillance—United States, 2019, CTRS. FOR
DISEASE CONTROL & PREVENTION MORBIDITY & MORTALITY WKLY. REP., Nov. 26, 2021, at 1, 1.
The CDC estimated that, as of 2019, 43.7 percent of all abortions in the U.S. were chemical
abortions. See id. at 6 (reporting that the number of chemical abortions increased by 12.5
percent between 2018 and 2019).
4
Mary Davenport et al., Embryo Survival After Mifepristone: A Systematic Review of the
Literature, 32 ISSUES L. & MED. 3, 4–7 (2017) (reviewing the history of development). Since
RU-486 was named by Roussel Uclaf, numerous brand names, generic names, and labels
have been used. We use the term “chemical” abortion for several practical and medical
reasons. First, it clearly distinguishes the method from surgical abortion and allows that
there may be additional chemical forms now or in the future. Second, both surgical and RU486 abortion has some “medical” aspect, so “medical abortion” is not a clear descriptor.
Third, RU-486 involves a two-drug regimen with two chemicals, mifepristone, an antiprogestin, and misoprostol, a prostaglandin, each of which has unique properties, effects,
and risks. The risks of each need to be specifically examined as fully as possible if women are
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chemical abortion.5 Some are now promoting a misoprostol-only abortion.6
Some are attempting to de-medicalize chemical abortion entirely and make
it over-the-counter (OTC), do-it-yourself (DIY), or by mail-order, thereby
eliminating physician involvement.
Mail-order and DIY abortions have obvious risks, as exemplified by the 2013
case of Patel v. State.7 The Indiana Court of Appeals described the case:
Thirty-two-year-old Purvi Patel managed her father’s
restaurant in Mishawaka[, Indiana]. A relationship with a
restaurant employee resulted in her pregnancy. In June 2013,
she purchased mifepristone and misoprostol online from a
Hong Kong pharmacy and used those drugs to terminate the
pregnancy at home. On the evening of July 13, she delivered
a live baby of approximately twenty-five to thirty weeks
gestation who died shortly after birth. She drove to the
restaurant, put the baby in a nearby dumpster, and drove
herself to the emergency room.8
to give fully informed consent and if legislators are going to be sufficiently informed to adopt
effective policy. Fourth, if the current plans of many abortion advocates to de-medicalize
chemical abortion are realized, mifepristone and/or misoprostol may become over-thecounter (OTC) or do-it-yourself (DIY), doctors will be excluded, and “medical abortion” will
no longer be meaningful. See VICE News, Inside Texas’s Underground Abortion Pill Network,
YOUTUBE (Feb. 9, 2022), https://www.youtube.com/watch?v=CR3uexqGgXo (discussing the
use of misoprostol without physician involvement and the trafficking of misoprostol
between Texas and Mexico). Some states also employ the term “chemical abortion.” IDAHO
CODE § 18-617(1)(b) (2022) (defining “chemical abortion”).
5
See, e.g., Carrie N. Baker, Self-Managed Abortion is Medically Very Safe. But is it Legally
Safe?, MS. (Apr. 1, 2020), https://msmagazine.com/2020/04/01/self-managed-abortion-ismedically-very-safe-but-is-it-legally-safe/. See infra notes 54, 132.
6
See VICE News, supra note 4.
7
Patel v. State, 60 N.E.3d 1041 (Ind. Ct. App. 2016).
8
Id. at 1043. Indiana prosecutors charged Patel with violating two Indiana laws: a statute
criminalizing the neglect of a dependent and a “feticide” statute, and the court stated that the
“feticide” statute was not intended to regulate the unique legal and medical aspects of chemical
abortion. Id. at 1044. The neglect statute had existed for decades. IND. CODE ANN. § 35-46-1-4
(2021). The “feticide” statute was first enacted in 1979, years before RU-486 was developed.
Patel, 60 N.E.3d at 1058. A jury found Patel guilty of violating both statutes. Id. at 1044. At trial,
there was evidence that Patel’s baby was born alive. Id. at 1047–48, 1050. The question was
whether Patel caused the death, and the appeals court held that the state did not prove
beyond a reasonable doubt that Patel caused the death by failing to secure medical care for
the baby. Id. at 1044. Since there was sufficient evidence of neglect, but not enough to prove
it as the cause of death, the appeals court reduced the neglect charge. Id. at 1055. The court
also held that the “feticide” statute could not be used against a woman for her own abortion
because the Indiana legislature never intended the statute to apply to self-abortion, and the
appeals court vacated Patel’s “feticide” conviction. Id. at 1044.
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State authority to specifically regulate and address the unique risks of
chemical abortion has been tied up in litigation challenging the
constitutionality of such regulations based on Roe v. Wade9 and Planned
Parenthood v. Casey.10 The constitutionality of abortion regulations may
change with the outcome of Dobbs v. Jackson Women’s Health Organization,
a case challenging the constitutionality of Mississippi’s fifteen-week limit on
abortion,11 because the State of Mississippi has pressed the overruling of Roe
and Casey in both briefs and oral argument. After Dobbs, the states may have
greater authority to regulate or prohibit chemical abortion.
In this Article, we will start by providing an overview of chemical abortion,
its nature, and its risks, as reflected in medical literature and governmental
reports. Next, we will examine the lack of adequate federal governmental
oversight since 2000. The FDA approved mifepristone and misoprostol in
2000 with limited restrictions, and the FDA loosened those restrictions in
2016, enabling doctors to prescribe abortion later in pregnancy and
eliminating the reporting requirements for complications less than death.12
In 2021, the FDA rescinded the in-person administration requirement that
the FDA had required since 2000.13 Given the vacuum of federal oversight,
we will address the prospects for state regulation. As of 2022, few states have
comprehensive regulations that specifically address the unique nature and
risks of chemical abortion. Given the inherent medical risks of mifepristone
and misoprostol and the history of inadequate federal oversight, the states
have compelling interests in regulating mifepristone and misoprostol. These
interests are strengthened by the prospect that chemical abortion will be
increasingly available by mail-order for DIY abortions.

9

Roe v. Wade, 410 U.S. 113 (1973).
Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833 (1992); see FDA v. Am. Coll. of
Obstetricians & Gynecologists, 141 S. Ct. 10, 10–11 (2020) (granting stay of district court
injunction). The unconstitutionality of federal in-person administration would obviously
apply to similar state regulations. See e.g., Planned Parenthood of the Heartland, Inc. v. Iowa
Bd. of Med., 865 N.W.2d 252, 262–69 (Iowa 2015).
11
Jackson Women’s Health Org. v. Dobbs, 945 F.3d 265 (5th Cir. 2019), cert. granted, 141
S. Ct. 2619 (2021).
12
Kathi A. Aultman et al., Death and Severe Adverse Events After the Use of Mifepristone
as an Abortifacient From September 2000 to February 2019, 36 ISSUES L. & MED. 3, 23 (2021)
(“In March 2016, the FDA substantially reduced the prescribing requirements and changed
the drug protocol and yet at the same time eliminated reporting requirements except for
deaths. With the later relaxation of reporting requirements, the ability to perform any
relevant post-marketing evaluation of mifepristone was lost.”).
13
See Letter from Patrizia Cavazzoni, M.D., Dir. Ctr. Drug Evaluation & Rsch., FDA, to
Graham Chelius, M.D., Soc’y. Fam. Plan. (Dec. 16, 2021),
https://s3.documentcloud.org/documents/21155575/fda_letter_to_chelius.pdf.
10
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II. THE DEVELOPMENT OF CHEMICAL ABORTION IN THE U.S.
A.

The Anglo-American Legal Heritage Protecting Prenatal Human Beings

Evaluating state policy on abortion after Dobbs requires an understanding of
the history of abortion law. The American colonies inherited and adopted the
English common law protecting prenatal human lives from abortion and
homicide.14 Two common law rules governed: the quickening rule and the born
alive rule.15 The common law quickening rule was an evidentiary rule intended
to establish sufficient proof that a woman was pregnant with a living child.16
Under the rule, until a woman felt fetal movement (quickening), there was
insufficient proof of a living child (and pregnancy).17 Proof of a live pregnancy
was necessary for a charge of abortion (terminating a pregnancy), but not
sufficient to prove homicide of a prenatal child.
That was the purpose of the common law born alive rule, also an evidentiary
rule.18 Live birth was required for sufficient proof of homicide, the killing of a
human being.19 At a time of primitive medical understanding and a high infant
mortality rate, if an infant was stillborn, the born alive rule prevented a charge
of homicide because the law deemed there to be insufficient proof to distinguish
between natural and criminal (human) causes of prenatal death.20 An individual
could be prosecuted for homicide only if the infant was born alive (observed
outside the womb at any stage of pregnancy showing signs of life) and died
thereafter from injuries inflicted while in utero (prenatal injuries).21 A critical
element of the born alive rule was that there was no gestational limit.22 Neither
14

DELLAPENNA, supra note 1, at 211–28 (2006). Dellapenna stated: “We are left then with
the conclusion that the English law regard ing [sic] abortion was fully received in the
colonies, and that the purported ‘common law liberty’ to abort is a myth.” Id. at 228. See also
2 JAMES WILSON, THE COLLECTED WORKS OF JAMES WILSON 1068 (Kermit L. Hall & Mark
David Hall eds., 2007) (“With consistency, beautiful and undeviating, human life, from its
commencement to its close, is protected by the common law. In the contemplation of law,
life begins when the infant is first able to stir in the womb. By the law, life is protected not
only from immediate destruction, but from every degree of actual violence, and, in some
cases, from every degree of danger.”).
15
Clarke D. Forsythe, Homicide of the Unborn Child: The Born Alive Rule and Other
Legal Anachronisms, 21 VAL. U. L. REV. 563, 567 (1987).
16
Id. at 568.
17
Id. at 567–68.
18
Id. at 567.
19
Id. at 575–76, 576 nn.59–60.
20
Id. at 575.
21
Forsythe, supra note 15, at 575–76.
22
Id. at 591 & nn.132–34; see Regina v. West, 2 C. & K. 784, 175 Eng. Rep. 329 (1848)
(allowing a homicide charge where an infant aborted alive died from prematurity); see also
DELLAPENNA, supra note 1, at 464.
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viability nor quickening limited the born alive rule.23 Hence, the prosecution
could bring a homicide charge if the child was injured at any time during
pregnancy and then born alive before dying of injuries inflicted while in the
womb.24 This was equally true if the child was born alive early in gestation from
a prenatal assault and then died from prematurity.25 The born alive rule was a
rule of location, not gestation.26 And if the child was born alive, quickening
was obsolete and no longer relevant. These common law rules protected the
life of the developing prenatal human being from the earliest point that it could
be determined to be alive. 27 By the time of Roe, state courts and legislatures had
enhanced this common law protection through prenatal injury, wrongful death,
and fetal homicide laws.28
These common law rules demonstrate that the law was dependent on the
medical understanding at the time the law developed. Abortion law and
medicine have always been inextricably intertwined. Medicine and technology
affected the law’s ability to prove a live pregnancy or the corpus delicti of
homicide.29 Contrary to folk tales, during the years of the common law there
were no means of abortion that were both effective and safe.30 Common law
decisions and literature provide evidence that abortion providers attempted
23

DELLAPENNA, supra note 1, at 464 & n.85; Forsythe, supra note 15, at 591 & nn.132–37.
See Forsythe, supra note 15, at 591 & nn.132–36.
25
Id. The prenatal application of the born alive rule is confirmed by numerous
authorities. Id. at 584, 583–84 n.92, 585, 586 n.106 (first quoting R. v. Sims (1600) 75 Eng.
Rep. 1075, 1076; then quoting EDWARD COKE, THE THIRD PART OF THE INSTITUTES OF THE
LAWS OF ENGLAND 50 (Garland Publ’g. 1979) (1628); then quoting 1 WILLIAM BLACKSTONE,
COMMENTARIES *126; and then quoting 1 WILLIAM HAWKINS, A TREATISE OF THE PLEAS OF THE
CROWN § 16 (Garland Publ’g. 1978) (1716)).
26
See id. at 591 n.134 (“If a person intending to procure abortion causes a child to be
born so soon that it cannot live, and it does in consequence, this is murder, though no bodily
injury be inflicted on the child.” (quoting 2 WILLIAM RUSSELL, A TREATISE ON CRIMES AND
MISDEMEANORS 670–72 (Garland Publ’g. 1979) (1865))).
27
See id. at 591 & nn.132–37.
28
Paul Benjamin Linton, The Legal Status of the Unborn Child Under State Law, 6 U. ST.
THOMAS J.L. & PUB. POL’Y 141, 143–50 (2011); William J. Maledon, Note, The Law and the
Unborn Child: The Legal and Logical Inconsistencies, 46 NOTRE DAME LAW. 349, 356–58,
365–66 (1971).
29
Forsythe, supra note 15, at 565–80.
30
See DELLAPENNA, supra note 1, at 3–56. “[T]he ingestion and insertion techniques, if
effective, appear to have been nearly as deadly as the batterings and other injury techniques.”
Id. at 31. “Ingestion techniques were nearly as painful and deadly as the worst injury
techniques until well into the nineteenth century . . . .” Id. at 37. “American courts in [the]
nineteenth century were well aware of the limited effectiveness of such ‘potions’ unless taken
in doses dangerous to the health or the life of the mother.” Id. at 49. “As we saw in chapter 1,
abortion techniques were so crude before 1800 as virtually to amount to suicide . . . .” Id. at
57.
24

384

LIBERTY UNIVERSITY LAW REVIEW

[Vol. 16:3

three types of abortion techniques—injury (battery), intrusion (an instrument),
and ingestion (a potion or substance).31 But there is no reliable evidence that
any of the techniques were effective (producing a completed abortion) or safe
(not killing the mother).32 Abortion could not be considered safe if it killed the
mother, as many potions and devices did.33 Thus, most states enacted legislation
prohibiting abortion with the intent to protect both mother and unborn child.34
Abortion techniques before the nineteenth century were both dangerous to
the mother and minimally effective.35 Then, with the distribution and wider
usage of antibiotics after World War II—another example of technological
change—and the introduction of new techniques, induced abortion became less
dangerous for the mother around mid-century.36 As Mary Calderone, then
Medical Director for Planned Parenthood, noted in 1960, only 260 abortionrelated deaths were reported in 1957.37 Although virtually all states prohibited
abortion except to save the life of the mother until 1966, several states loosened
their abortion laws between 1967 and 1973.38 Still, in the 1973 case of Roe v.
Wade, the Supreme Court struck down the laws of all fifty states and legalized

31

DELLAPENNA, supra note 1, at 31.
See id.
33
See id.
34
Id. at 286 & n.198 (collecting cases explaining the purpose of nineteenth century state
abortion laws). See generally James S. Witherspoon, Reexamining Roe: Nineteenth Century
Abortion Statutes and the Fourteenth Amendment, 17 ST. MARY’S L.J. 29 (1985) (showing the
protective purposes of nineteenth century abortion statutes).
35
DELLAPENNA, supra note 1, at 454. See also Anita Bernstein, Common Law
Fundamentals of the Right to Abortion, 63 BUFF. L. REV. 1141, 1193 (2015) (“Dellapenna
argues persuasively that this combination [safety and effectiveness] did not come together
until the nineteenth century.”).
36
DELLAPENNA, supra note 1, at 454.
37
Mary Steichen Calderone, Illegal Abortion as a Public Health Problem, 50 AM. J. PUB.
HEALTH 948, 949 (1960).
38
See Roe v. Wade, 410 U.S. 113, 117–18, 140 & n.37 (1973).
32
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abortion in every state, at every stage of gestation, for virtually any reason.39 The
States then had the burden to fill the legal vacuum created by Roe v. Wade.40
B.

The Concept of Elective Abortion & Informed Consent

The Supreme Court in Roe assumed that legal abortion would involve a
woman’s regular physician in a medical decision about whether to have an
abortion and that a medical judgment was always involved in deciding whether
an abortion should be done.41 But elective abortion in the U.S. has not turned
out that way.42 Elective abortion is significantly different from medically39
See id. at 162–64 (holding that the state has no interest in prohibiting abortion until the
“compelling” point of viability and that abortion may be prohibited at viability unless
abortion is necessary to preserve the life or health of the mother); Doe v. Bolton, 410 U.S.
179, 192 (1973) (“[A]ll factors -- physical, emotional, psychological, familial, and the
woman’s age -- [are] relevant to the well-being of the patient. All these factors may relate to
health.”); Laurence H. Tribe, Foreword: Toward a Model of Roles in the Due Process of Life
and Law, 87 HARV. L. REV. 1, 2 (1973) (“And in Roe v. Wade and Doe v. Bolton, when the
Court had its most dramatic opportunity to express its supposed aversion to substantive due
process, it carried that doctrine to lengths few observers had expected, imposing limits on
permissible abortion legislation so severe that no abortion law in the United States remained
valid.”).
40
See CLARKE D. FORSYTHE, ABUSE OF DISCRETION: THE INSIDE STORY OF ROE V. WADE
217–18 (2013) (“The Public Health Vacuum the Justices Created”).
41
See Roe, 410 U.S. at 163 (“[F]or the period of pregnancy prior to this ‘compelling’
point, the attending physician, in consultation with his patient, is free to determine, without
regulation by the State, that, in his medical judgment, the patient’s pregnancy should be
terminated.”); id. at 165–66 (“The decision vindicates the right of the physician to administer
medical treatment according to his professional judgment up to the points where important
state interests provide compelling justifications for intervention. Up to those points, the
abortion decision in all its aspects is inherently, and primarily, a medical decision, and basic
responsibility for it must rest with the physician.”); Doe, 410 U.S. at 208 (Burger, C.J.,
concurring) (“[T]he vast majority of physicians observe the standards of their profession,
and act only on the basis of carefully deliberated medical judgments relating to life and
health.”).
42
See City of Akron v. Akron Ctr. for Reprod. Health, 462 U.S. 416, 473 (1983)
(O’Connor, J., dissenting) (“It is certainly difficult to understand how the Court believes that
the physician-patient relationship is able to accommodate any interest that the State has in
maternal physical and mental well-being in light of the fact that the record in this case shows
that the relationship is non-existent.”); Planned Parenthood of Cent. Mo. v. Danforth, 428
U.S. 52, 91 (1976) (Stewart, J., concurring) (“It seems unlikely that she [a pregnant minor]
will obtain adequate counsel and support from the attending physician at an abortion clinic,
where abortions for pregnant minors frequently take place.”). See generally Mary Anne
Wood & W. Cole Durham, Jr., Counseling, Consulting, and Consent: Abortion and the
Doctor-Patient Relationship, 1978 BYU L. REV. 783, 793–802 (1978) (identifying as part of
the doctor-patient relationship: screening, informing the patient as to the nature and
consequences of the procedure, consideration of alternatives, and the conscious exercise of
medical judgment).
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indicated procedures. Elective abortion does not treat any illness or disease,
and there is no medical reason to interrupt a healthy pregnancy in a healthy
mother with surgery or drugs.43 Elective abortion’s primary objective is the
death of the prenatal child, as evidenced by the testimony of abortion providers
during the Gonzales v. Carhart44 litigation.45
As with any medical intervention, there are both short-term and long-term
risks and consequences. Any surgical procedure involves the risk of bleeding,
infection, and damage to the organ being worked on or the organs nearby. A
surgical abortion can damage any of the woman’s reproductive organs. Because
nearly one out of twenty women require surgery after a chemical abortion done
at the earliest gestational ages (sometimes emergently), the risks of reproductive
43

See, e.g., Elective abortion, BRITANNICA, https://www.britannica.com/science/electiveabortion (last visited Mar. 6, 2022) (“An elective abortion is the interruption of a pregnancy
before the 20th week of gestation at the woman’s request for reasons other than maternal
health or fetal disease. Most abortions in the United States are performed for this reason.”);
Elective abortion, FARLEX, INC., https://medicaldictionary.thefreedictionary.com/elective+abortion (last visited Mar. 6, 2022) (“[E]lective
abortion [is an] induced abortion done at the request of the mother for other than
therapeutic reasons.”); Elective abortion, FERTILITYPEDIA, https://fertilitypedia.org/edu/riskfactors/elective-abortion (last visited Mar. 6, 2022) (“An abortion is referred to as an elective
or voluntary abortion when it is performed at the request of the woman for non-medical
reasons.”).
44
See Gonzales v. Carhart, 550 U.S. 124, 168 (2007) (upholding the constitutionality of the
federal Partial Birth Abortion Ban Act (PBABA)).
45
See id. at 167–68. As the Court recorded in its opinion in Gonzales:
Yet one doctor would not allow delivery of a live fetus younger than
24 weeks because “the objective of [his] procedure is to perform an
abortion,” not a birth. The doctor thus answered in the affirmative when
asked whether he would “hold the fetus’ head on the internal side of the
[cervix] in order to collapse the skull” and kill the fetus before it is born.
Another doctor testified he crushes a fetus’ skull not only to reduce its
size but also to ensure the fetus is dead before it is removed. For the staff
to have to deal with a fetus that has “some viability to it, some movement
of limbs,” according to this doctor, “[is] always a difficult situation.”
Id. at 139–40 (alterations in original) (citations omitted); see also Planned
Parenthood Ass’n of Kan. City, Mo., Inc. v. Ashcroft, 462 U.S. 476, 483 n.7 (1983).
The Court noted:
His disinterest in protecting fetal life is evidenced by his agreement “that
the abortion patient has a right not only to be rid of the growth, called a
fetus in her body, but also has a right to a dead fetus.” He also agreed
that he “[never] [has] any intention of trying to protect the fetus, if it can
be saved,” and finally that “as a general principle” “[there] should not be
a live fetus.”
Id. (alterations in original) (citations omitted). See generally 18 U.S.C. § 1531.
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organ damage from surgical intervention pertain to chemical abortions as
well.46 Worse, the risks of chemical abortions rise rapidly after ten weeks
gestation so that abortions after thirteen weeks of pregnancy result in one out
of every three women needing surgery for hemorrhage or tissue left inside.47
Elective abortion is not medical care but rather the use of surgery or drugs to
end a pregnancy for social reasons.48 The social reasons displace necessary
medical analysis which examines the abnormal medical condition that requires
treatment and medical indications for the intervention, compares the various
alternative interventions, and discusses these with the patient.49 It skews and
short-cuts the decision-making and informed consent process.50 Abortion
providers often assume that the client has made the decision before walking into
the clinic.51 Because elective abortion is not medically necessary for anything,
no discussion of alternatives are necessary, and no discussion of risks are
relevant. By skewing and short cutting the decision-making process, elective
abortion cannot produce fully informed consent for the woman.
1.

The Discovery & Development of RU-486

Medical technology has long shaped the efficacy of abortion techniques,
the enforceability of abortion law, and the language of abortion statutes.52
Medical technology for terminating pregnancy has evolved from primitive
methods to the development in France of the curved blade (curette) in the
nineteenth century to the development in the 1960s of the flexible plastic
suction curettage cannula.53 This has led increasingly toward chemical
46
Maarit J. Mentula et al., Immediate Adverse Events After Second Trimester Medical
Termination of Pregnancy: Results of a Nationwide Registry Study, 26 HUM. REPROD. 927, 929,
931 tbl. II (2011).
47
Id.
48
See supra note 43. And the presumed empirical evidence that abortion is good for
women is, to say the least, thin. See generally Helen M. Alvare, Nearly 50 Years Post-Roe v.
Wade and Nearing its End: What is the Evidence that Abortion Advances Women’s Health
and Equality?, 34 REGENT U. L. REV. 165 (2022).
49
See Wood & Durham, supra note 42, at 793–800.
50
See id.
51
See, e.g., Government-Mandated Delays Before Abortion, ACLU,
https://www.aclu.org/other/government-mandated-delays-abortion (last updated Jan. 2003)
(“In reality, almost all women, by the time they arrive at a clinic, are very clear about their
reasons for wanting an abortion.”).
52
See generally DELLAPENNA, supra note 1, chs. 1, 5, 6, 12; Joseph W. Dellapenna, The
History of Abortion: Technology, Morality, and Law, 40 U. PITT. L. REV. 359 (1979).
53
Danielle B. Cooper & Gary W. Menefee, Dilation and Curettage, NCBI BOOKSHELF,
https://www.ncbi.nlm.nih.gov/books/NBK568791/ (last updated Dec. 16, 2021) (“History
documents the first cervical dilators available in the early 19th century. Joseph-Claude-
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abortion, which abortion providers hope will increase access, eliminate the
need for doctors, and allow DIY abortions.54
In the 1980s, a French chemist, Etienne-Emile Baulieu, worked at the
pharmaceutical company Roussel Uclaf on a drug named RU-38486—later
shortened to RU-486, generic name, mifepristone.55 The drug blocked a
specific cellular receptor called the glucocorticoid receptor.56 This receptor
blockade is important in treating Cushing’s syndrome, the initial reason for
pharmaceutical interest.
Mifepristone also blocks a second cellular receptor called the progesterone
receptor, by binding with a woman’s progesterone receptors on the nuclear
membranes of cells in the uterus, ovary, brain, breast, and immune system.57
Progesterone is the natural hormone which changes a woman’s body to allow
her to carry and nurture a pregnancy. With mifepristone blocking the
connection of progesterone to progesterone receptors in the uterus of a
pregnant woman, the mother’s cells in the placenta stop functioning, which
eventually leads to the death of the embryo through, in essence, starvation.58
Anthelme Récamier (6 November 1774–28 June 1852) is credited with the invention of the
first curette in 1843, which resembled a small scoop or spoon with a long handle.”); World
Health Org. Task Force on Sequelae of Abortion, Comparison of Rigid and Flexible Cannulae for
Early Abortion without Cervical Dilatation, 15 STUD. FAM. PLAN. 79, 79 (1984); Tanfer Emin Tunc,
Designs of Devices: The Vacuum Aspirator and American Abortion Technology, 28 DYNAMIS
353, 370 (2008), https://scielo.isciii.es/pdf/dyn/v28/15.pdf.
54
See infra notes 128, 129; see also, e.g., Anastasia Toufexis, Abortions Without Doctors,
TIME, Aug. 28, 1989, at 66; DELLAPENNA, supra note 1, at 831 & n.422 (“Despite all the hype,
however, the approval of the abortion pill initially made little difference because few doctors
were enthusiastic about using it.”); id. at 670 (referring to “‘underground’ groups for
performing abortions” in the 1960s; “‘Jane’ reached its stride when the women involved
decided they could do the abortions themselves and dispense with physicians except as a
backup. At its peak, between 1969 and 1973, ‘Jane’ was doing 3,000 abortions a year . . . .”).
55
See THE ANTIPROGESTIN STEROID RU 486 AND HUMAN FERTILITY CONTROL (EtienneEmile Baulieu & Sheldon J. Segal eds., 1985) [hereinafter BAULIEU & SEGAL].
56
Ralph P. Miech, Pathophysiology of Mifepristone-induced Septic Shock Due to
Clostridium Sordellii, 39 ANNALS PHARMACOTHERAPY 1483, 1484 (2005),
https://pubmed.ncbi.nlm.nih.gov/16046483/.
57
See generally Katherine M. Scarpin et al., Progesterone Action in Human Tissues:
Regulation by Progesterone Receptor (PR) Isoform Expression, Nuclear Positioning and
Coregulator Expression, NUCLEAR RECEPTOR SIGNALING, Dec. 31, 2009, at 1 (“Progesterone is
an essential regulator of normal human female reproductive function in the uterus, ovary,
mammary gland and brain, and also plays an important role in non-reproductive tissues
such as the cardiovascular system, bone and the central nervous system, highlighting the
widespread role of this hormone in normal physiology.”).
58
U.S. H.R. GOV’T REFORM COMM., SUBCOMM. ON CRIM. JUST., DRUG POL’Y, & HUMAN
RES., THE FDA AND RU-486: LOWERING THE STANDARD FOR WOMEN’S HEALTH 4 (2006)
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When progesterone is insufficient, the woman loses the pregnancy. Baulieu
realized that this new drug might be able to be developed as an abortifacient.59
However, the blockade of glucocorticoid receptors also induces an
unexpected immune blockade, suppressing the immune system, which can
result in increased susceptibility to overwhelming infection.60
In the drug development process, Baulieu’s report included a study which
graphed the rate at which RU-486 could be removed from the progesterone
receptor, in the presence of high concentrations of progesterone.61 This
pharmacokinetic study clearly shows that mifepristone’s blockade of
progesterone receptors is reversible—not permanent—and that high
concentrations of progesterone will reverse the binding of mifepristone at the
progesterone receptor.62
Scientists conducted additional animal model experiments to test the
reversibility of mifepristone binding and to determine if natural progesterone
could overcome the abortifacient effects in animal models. In 1989, Yamabe
conclusively determined that, in rats, the administration of additional natural
progesterone could overcome the mifepristone blockage of progesterone
[hereinafter House Subcommittee Staff Report] (“RU-486 terminates pregnancy by blocking
progesterone receptors in the uterus, a hormone necessary for the maintenance of
pregnancy. This leads to degeneration of the uterine lining, blocking nutrition to the prenate,
thus resulting in its death.”).
59
BAULIEU & SEGAL, supra note 55, at 14–15. See generally Etienne-Emile Baulieu,
Updating RU 486 Development, 20 L. MED. & HEALTH CARE 154, 155–56 (1992).
60
Jeanette I. Webster & Ester M. Sternberg, Role of the Hypothalamic-Pituitary-Adrenal
Axis, Glucocorticoids and Glucocorticoid Receptors in Toxic Sequelae of Exposure to Bacterial
and Viral Products, 181 J. ENDOCRINOLOGY 207, 207–17 (2004); Miech, supra note 56, at
1484; Marc Fischer et al., Fatal Toxic Shock Syndrome Associated with Clostridium Sordellii
after Medical Abortion, 353 NEW ENG. J. MED. 2352, 2352–54, 2358 (2005) (reporting four
deaths “after abortions that were medically induced with 200 mg of oral mifepristone and
800 ug of vaginal misoprostol”); House Subcommittee Staff Report, supra note 58, at 32–35.
61
BAULIEU & SEGAL, supra note 55, at 91 fig.3.
62
George Delgado & Mary Davenport, Progesterone Use to Reverse the Effects of
Mifepristone, 46 ANNALS PHARMACOTHERAPY 1723, 1723 (2012) (case report); George
Delgado et al., A Case Series Detailing the Successful Reversal of the Effects of Mifepristone
Using Progesterone, 33 ISSUES L. & MED. 21, 26, 27 tbl.1 (2018). See also Ruth Graham, A New
Front in the War Over Reproductive Rights: ‘Abortion-Pill Reversal,’ N.Y. TIMES (July 18,
2017), https://www.nytimes.com/2017/07/18/magazine/a-new-front-in-the-war-overreproductive-rights-abortion-pill-reversal.html (“‘It makes biological sense,’ says Dr. Harvey
Kliman, director of the reproductive and placental research unit at the Yale School of
Medicine. ‘I think this is actually totally feasible.’ Kliman, who has published research on
progesterone and miscarriage, is in favor of abortion rights, and made clear he wasn’t
advocating widespread use of the treatment. But if one of his daughters came to him and said
she had somehow accidentally taken mifepristone during pregnancy, he said, he would tell
her to take 200 milligrams of progesterone three times a day for several days, just long
enough for the mifepristone to leave her system. ‘I bet you it would work.’”).
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receptors and its abortifacient properties.63 That study separated pregnant
rats into three groups. The first group received no drugs, the second group
received mifepristone, and the third group received mifepristone followed by
natural progesterone.64 Every member of the no-drug group delivered live
offspring.65 Only 33.3% of the mifepristone-only group delivered live
offspring.66 One hundred percent of the third group, which received
mifepristone and then progesterone, delivered live offspring.67 This
experiment effectively demonstrated that the mifepristone blockade can be
overcome by the presence of sufficient natural progesterone to out-compete
mifepristone at the progesterone receptor.68
Studies about the use of mifepristone to induce abortion in human beings
show that the use of mifepristone alone at the current dosage used today (200
mg.) is associated with fetal survival rates from 10%–23%.69 This fetal survival
rate was considered unacceptable for an effective abortion-inducing drug.70
Thus, early in the development of the current drug regimen scientists added
a second drug, a prostaglandin, which is administered twenty-four to fortyeight hours after mifepristone. The prostaglandin induces powerful uterine
contractions, which cause the expulsion of the fetus and placenta.71 For
pregnancies less than forty-nine days from the first day of the woman’s last
menstrual period (LMP), the combination of mifepristone and misoprostol
causes the complete expulsion of both human embryo and placenta in about
95% of pregnancies.72 However, this effectiveness declines significantly as the
age of the pregnancy advances, such that by thirteen weeks, approximately
one out of every three women who attempt abortion with mifepristone and
misoprostol need emergency surgery for hemorrhage or retained tissue.73

63
Shingo Yamabe et al., The Effect of RU486 and Progesterone on Luteal Function During
Pregnancy, PUBMED (May 20, 1989), https://pubmed.ncbi.nlm.nih.gov/2776921/. See the
discussion of Yamabe in Davenport et al., supra note 4, at 5–6.
64
Id.
65
Id.
66
Id.
67
Id.
68
Id. The progesterone infusion process is being challenged by the American Medical
Association (AMA) in federal court litigation in North Dakota. Complaint at 1, 14–16, AMA
v. Stenehjem, No. 1:19-cv-125 (D.N.D. June 25, 2019).
69
Davenport et al., supra note 4, at 14–15 tbl.
70
Id. at 4, 6.
71
Id. at 4.
72
Mentula et al., supra note 46, at 931 fig.2.
73
See id.
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FDA Approval of RU-486

The French pharmaceutical company Roussel Uclaf initially prohibited the
commencement of any new studies in the United States and stated that “‘under
no circumstance[s]’ would it permit a new drug application to be filed with [the]
FDA.”74 However,
[O]n January 22, 1993, President Clinton directed Department
of Health and Human Services [] Secretary Donna Shalala to
assess initiatives to promote the testing and licensing of
mifepristone or other antiprogestins in the United
States. . . . President Clinton reportedly “wrote to Hoechst
asking the company to file a new drug application with the
FDA (an unprecedented situation in the pharmaceutical
industry!), which Hoechst intransigently refused to do.”
In early 1993, Secretary Shalala and FDA Commissioner David
Kessler “communicated with senior Roussel Uclaf officials to
begin efforts to pave the way for bringing RU-486 into the
American marketplace.” On May 16, 1994, the Population
Council reached an agreement with Roussel Uclaf, pursuant to
which the European drug maker transferred “without
renumeration, its United States patent rights for mifepristone
(RU-486) to the Population Council . . . .”75
On March 18, 1996, the Population Council/Planned Parenthood filed a new
drug application (NDA) with the FDA.76 However, to avoid legal liability, the
Population Council transferred the rights to manufacture and distribute RU486 to a shell company called Danco Laboratories, which was incorporated in
the Cayman Islands.77 Danco did not actually manufacture drugs, so Danco
74
Citizen Petition re: Request for Stay and Repeal of the Approval of Mifeprex
(mifepristone) for the Medical Termination of Intrauterine Pregnancy Through 49 Days’
Gestation at 8, FDA-2002-P-0364-0001 (Aug. 20, 2002) [hereinafter 2002 Citizen Petition],
https://aaplog.org/wp-content/uploads/2021/01/2002-Aug-Citizen-Petition_Mifeprex8.20.02.pdf.
75
Id. at 8–9; see also Katharine Q. Seelye, Accord Opens Way for Abortion Pill in U.S. in 2
Years, N.Y. TIMES (May 17, 1994), https://www.nytimes.com/1994/05/17/us/accord-opensway-for-abortion-pill-in-us-in-2-years.html (referring to the Clinton Administration’s
pressure on the manufacturer of RU-486 to apply for FDA approval).
76
2002 Citizen Petition, supra note 74, at 10.
77
See id. at 9 & n.25; DELLAPENNA, supra note 1, at 831 (“Danco Laboratories, LLC, the
company that undertook to market the drug, shrouded its activities and its very location in
secrecy in an effort to insulate itself from anti-abortion protestors. Whether because of the
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selected Hua Lian Pharmaceuticals, a Chinese drug manufacturer based in
Shanghai, to manufacture the drug.78 Shanghai Hua Lian Pharmaceuticals later
faced scandal and factory closures due to tainted drugs.79
The FDA based mifepristone’s approval on data from a single, non-blinded,
uncontrolled study of the effectiveness of mifepristone in the United States
conducted by the Population Council.80 The FDA usually requires two blinded,
randomized controlled trials as the basis of an NDA.81 In an unusual move, the
FDA not only allowed the one trial to serve as the sole study, but also admitted
additional manufacturer’s data, despite the fact that these data were impeached
by falsified and incomplete records as discovered on an FDA review:
The problems identified by the investigator suggested
carelessness, fraud, evidence tampering and the systematic
under-reporting of serious adverse events. The inspection
“revealed a failure to maintain complete and accurate records.”
The violations that were discovered included: “laboratory
reports that were missing” for 11 patients, “missing ultrasound
documents” for 20 patients, “pages missing from the case
record files and unreported aspirations [suction curettages],”
inclusion of 4 ineligible patients, and “consent forms were
dated after the start of study for some subjects, and the
investigator had signed consent form[s] sometimes in
advance, up to 4 days before the subjects had signed.” . . . After
elaborating on the deficiencies found, the FDA inspector
secrecy or because of fear for the profitability of the company, Danco had difficulty raising
capital until it was rescued by a $10,000,000 loan, made on advantageous terms by the David
and Lucille Packard Foundation.”).
78
2002 Citizen Petition, supra note 74, at 9–10; Philip P. Pan, Chinese to Make RU-486
for U.S., WASH. POST (Oct.12, 2000),
https://www.washingtonpost.com/archive/politics/2000/10/12/chinese-to-make-ru-486-forus/97e37b0f-a6fd-41f5-8ce3-d2af86adea63/.
79
SFDA Closes Down Shaghai Hualian Pharmaceutical, PINK SHEET: INFORMA PHARMA
INTEL. (Apr. 21, 2008), https://pink.pharmaintelligence.informa.com/SC068257/SFDACloses-Down-Shanghai-Hualian-Pharmaceutical; Jake Hooker & Walt Bogdanich, Tainted
Drugs Tied to Chinese Plant, CHI. TRIB. (Jan. 31, 2008),
https://www.chicagotribune.com/news/ct-xpm-2008-01-31-0801301033-story.html.
80
Irving M. Spitz et al., Early Pregnancy Termination With Mifepristone and Misoprostol
in the United States, 338 NEW ENG. J. MED. 1241, 1241–47 (1998); see House Subcommittee
Staff Report, supra note 58, at 16–19.
81
House Subcommittee Staff Report, supra note 58, at 15; see 21 U.S.C. § 355(d); 21
C.F.R. §§ 314.126(b)(2), (5); Jonathan J. Darrow, Crowdsourcing Clinical Trials, 98 MINN. L.
REV. 805, 852 (2014) (“Under the current system, these trials generally (but not always) are
randomized, controlled, and double-blinded.”).
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concluded: “Notwithstanding these objectionable conditions,
[redacted name of an FDA official] assured Dr. Aubeny that
he would not recommend that the studies not be included in
the evaluation of the NDA application.”82
Irregularities in the approval process continued.
Although the Population Council filed an NDA with the FDA for approval
of mifepristone as an abortifacient, it was clear that mifepristone must be used
in conjunction with misoprostol, which was manufactured by Searle.83 Searle
opposed the use of its drug in conjunction with mifepristone as an abortifacient
and did not file a Supplemental NDA for the use of misoprostol with
mifepristone.84 However, the FDA set an “extraordinary precedent” according
to a former FDA general counsel85 by requiring the unapproved use of
misoprostol as part of the approval of RU-486,86 a requirement which the FDA
had uncertain authority to mandate.87 Further, the FDA inexplicably waived the
Pediatric Rule, which required testing of drugs intended for use in the pediatric
population.88
In addition, the review process itself was truncated. The FDA initially began
a standard review, but later decided to grant an accelerated approval process
under Subpart H.89 By 2000, the FDA announced that it had “considered this
application under the restricted distribution regulations contained in 21 CFR
314.500 (Subpart H) and [had] concluded that restrictions as per [21] CFR
82

2002 Citizen Petition, supra note 74, at 40–41.
Id. at 10, 41–42.
84
Id. at 42 & n.190 (“Searle wrote an open letter to all health care practitioners stating
that ‘Cytotec is not approved for the induction of labor or abortion.’ The letter listed a
number of potential ‘[s]erious adverse events reported following off-label use of Cytotec in
pregnant women includ[ing] maternal or fetal death.’”); House Subcommittee Staff Report,
supra note 58, at 24 n.113 (citing Searle letter).
85
House Subcommittee Staff Report, supra note 58, at 23.
86
Id. (“When FDA approved the Population Council’s RU-486 application it also
mandated the use of another drug, misoprostol, as part of a two-drug regimen. The use of
misoprostol was not only an unapproved or off-label use – it was actually contraindicated at
that time.”); Rachel Zimmerman, FDA-Pharmacia Clash May Curb The Widespread Use of
RU-486, WALL ST. J. (Oct. 18, 2000, 12:01 AM),
https://www.wsj.com/articles/SB971827114427477389.
87
House Subcommittee Staff Report, supra note 58, at 23–25 (addressing lack of FDA
authority); 2002 Citizen Petition, supra note 74, at 43–45; Lars Noah, A Miscarriage in the
Drug Approval Process: Mifepristone Embroils the FDA in Abortion Politics, 36 WAKE FOREST
L. REV. 571, 590 (2001) (“Normally, the agency has no power to demand that manufacturers
add expanded indications to their drug labeling.”).
88
2002 Citizen Petition, supra note 74, at 76–77.
89
21 C.F.R. §§ 314.500–314.560 (Subpart H); DELLAPENNA, supra note 1, at 830; Noah,
supra note 87, at 580–81, 581 n.43; 2002 Citizen Petition, supra note 74, at 10 n.30.
83
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314.520 on the distribution and use of mifepristone are needed to assure safe
use of this product.”90 The FDA further explained that approval under Subpart
H “applies when [the] FDA concludes that a drug product shown to be effective
can be safely used only if distribution or use is restricted, such as to certain
physicians with certain skills or experience.”91 In fact, Subpart H was the only
mechanism the FDA had at the time to impose post-marketing restrictions on
the use of the drug,92 and some of these restrictions were later codified as the
Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, with
Elements to Assure Safe Use (ETASU).
The intent behind Subpart H was to accelerate the approval of drugs effective
for treating “serious or life-threatening illnesses.”93 According to the FDA’s selfreported data, by early 2002, the FDA had approved only thirty-eight NDAs
under Subpart H.94 “Of these approvals, 20 were for the treatment of HIV and
HIV-related diseases, nine were for the treatment of various cancers and their
symptoms, four were for severe bacterial infections, one was for [leprosy], one
was for hypotension, and, finally, one was for” the deliberate destruction of
prenatal human beings—mifepristone.95 However, it is clear that pregnancy is
not a disease, but rather a normal physiological process in which two human
beings are in a symbiotic, biological relationship. Elective abortion does not
“treat[] . . . serious or life-threatening disease.”96 From beginning to end, the
FDA’s approval of mifepristone represented a serious miscarriage in the drug
approval process.97
3.

Post-Marketing Restrictions

The irregularities continued after FDA approval. Despite the fact that the
FDA established post-marketing restrictions on the use of RU-486, abortion

90

2002 Citizen Petition, supra note 74, at 11.
Id.
92
2002 Citizen Petition, supra note 74, at 23.
93
See New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated
Approval, 57 Fed. Reg. 58942-01 (Dec. 11, 1992) (codified as amended at 21
C.F.R. § 314.500) (“treating serious or life-threatening illnesses”); see also Sheila R. Shulman
& Jeffrey S. Brown, The Food and Drug Administration’s Early Access and Fast-Track
Approval Initiatives: How Have They Worked?, 50 FOOD & DRUG L.J. 503, 503–04, 503–04 n.5
(1995); House Subcommittee Staff Report, supra note 58, at 20.
94
2002 Citizen Petition, supra note 74, at 19, 19 n.74.
95
Id. at 19.
96
New Drug, Antibiotic, and Biological Drug Product Regulations; Accelerated
Approval, 57 Fed. Reg. 58942-01 (Dec. 11, 1992) (codified as amended at 21
C.F.R. § 314.500); House Subcommittee Staff Report, supra note 58, at 20.
97
See Noah, supra note 87, at 571–73.
91
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advocates exhibited no sign that they would comply with FDA restrictions.98
Even the then-president of Danco Laboratories, Dr. Richard Hausknecht was
advertising the home administration of misoprostol and vaginal
administration of mifepristone on his website within weeks of the FDA
approval.99 Both of Dr. Hausknecht’s recommendations were contravened by
the FDA post-marketing restrictions.100 The FDA was aware of this breach
but took no action. Years later, the FDA codified some of the post-marketing
restrictions as a REMS with ETASU. This allowed the FDA to theoretically
impose financial sanctions for noncompliance. But to date, no financial
sanctions have ever been imposed, despite the fact that non-compliance with
the FDA REMS was the rule for the abortion industry.
In 2002, a Citizen Petition was filed with the FDA documenting the
aberrant drug approval process and the predictable risks of hemorrhage and
infection.101 The FDA did not respond for fourteen years.102 By 2005, five
women had died in North America from an overwhelming septic infection
caused by a common soil bacteria called Clostridium sordellii (abbreviated C.
sordellii).103 These unexpected, yet predictable deaths caught Danco and the
Population Council in the midst of their non-compliance.104 As noted earlier,
studies have shown that both mifepristone105 and misoprostol106 suppress a
woman’s immune response to infection, which can allow simple infections to
become overwhelming, leading to fatal sepsis. After the deaths of at least four
otherwise healthy women from fatal sepsis within two weeks of the use of
98

2002 Citizen Petition, supra note 74, at 71–72.
Id. at 71 n.309.
100
Id.
101
Id. at 1, 3; DEP’T OF HEALTH & HUM. SERVS., FDA-2002-P-0364-0002, CITIZEN DENIAL
RESPONSE FROM FDA CDER TO THE AMERICAN ASSOCIATION OF PRO LIFE OBSTETRICIANS AND
GYNECOLOGISTS, ET AL. 1 (2016).
102
DEP’T OF HEALTH & HUM. SERVS., supra note 101, at 1.
103
Dep’t of Health & Hum. Servs., Ctr. for Disease Control & Prevention, U.S. Food &
Drug Admin., Nat’l. Inst. of Health, Emerging Clostridial Disease Workshop 4, 78–80 (May
11, 2006),
https://aaplog.wildapricot.org/resources/2006%20CDC%20FDA%20Clostridial%20Disease%
20Transcript.pdf; Public Notice of Emerging Clostridial Disease Workshop, 71 Fed. Reg.
7778–79 (Feb. 14, 2006).
104
See 2002 Citizen Petition, supra note 74, at 65–66, 66 n.290.
105
See Jeanette I. Webster & Ester M. Sternberg, Role of the Hypothalamic-PituitaryAdrenal Axis, Glucocorticoids and Glucocorticoid Receptors in Toxic Sequelae of Exposure to
Bacterial and Viral Products, 181 J. ENDOCRINOLOGY 207, 212, 217 (2004); see also Miech,
supra note 56, at 1487.
106
David M. Aronoff et al., Misoprostol Impairs Female Reproductive Tract Innate
Immunity Against Clostridium Sordellii, 180 J. IMMUNOLOGY 8222, 8229 (2008).
99
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mifepristone—all had used the off-label vaginal administration of
misoprostol instead of the oral (buccal (pronounced “buckle”))
administration required by the FDA—the FDA and the Centers for Disease
Control and Prevention (CDC) convened a special meeting in May 2006 to
investigate the use of mifepristone in relationship to the septic deaths.107 In
fact, the concern about serious infections led Planned Parenthood to
abandon the off-label vaginal administration of misoprostol and substitute
instead the off-label use of misoprostol in the cheek (buccal
administration).108 However, deaths from Clostridium sordellii continue with
the current use of buccal administration.109
In October 2006, the U.S. House Subcommittee on Criminal Justice, Drug
Policy, and Human Resources held a special hearing to investigate the FDA’s
handling of mifepristone’s approval and lack of post-marketing
surveillance.110 The 40-page Staff Report concluded that the FDA had been
deficient in handling both the approval of mifepristone and the surveillance
of the drug’s post-marketing complications.111
In 2016, the FDA relaxed the initial post-marketing restrictions imposed
in 2000.112 On the same day, the FDA also finally answered the Citizen
Petition filed in 2002 that documented the irregularities of the approval and
post-marketing use and requested the repeal of the approval.113 Remarkably,
the FDA did not contest the substantial findings of the Petition, but simply
dismissed by fiat the documented concerns.114 In relaxing the restrictions in
2016, the FDA no longer required prescribers to submit Adverse Event

107

Dep’t of Health & Hum. Servs., Ctr. for Disease Control & Prevention, U.S. Food &
Drug Admin., Nat’l. Inst. of Health, Emerging Clostridial Disease Workshop 4, 78–80 (May
11, 2006),
https://aaplog.wildapricot.org/resources/2006%20CDC%20FDA%20Clostridial%20Disease%
20Transcript.pdf; Public Notice of Emerging Clostridial Disease Workshop, 71 Fed. Reg.
7778–79 (Feb. 14, 2006).
108
Mary Fjerstad et al., Rates of Serious Infection After Changes in Regimens for Medical
Abortion, 361 NEW ENG. J. MED. 145, 145 (2009).
109
U.S. FOOD & DRUG ADMIN., MIFEPRISTONE U.S. POST-MARKETING ADVERSE EVENTS
SUMMARY THROUGH 12/31/2018 (2019), https://www.fda.gov/media/112118/download.
110
House Subcommittee Staff Report, supra note 58, at 3. The May 17, 2006, hearing
before the House Subcommittee is available at:
https://www.govinfo.gov/content/pkg/CHRG-109hhrg31397/html/CHRG109hhrg31397.htm (transcript).
111
Id. at 38, 40.
112
Aultman et al., supra note 12, at 23–24, 24 nn.47–48.
113
DEP’T OF HEALTH & HUM. SERVS., supra note 101, at 1.
114
See id.
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Reports and only required the reporting of deaths.115 As expected, the
number of Adverse Event Reports dropped precipitously after prescribers
were no longer required to report hospitalizations, hemorrhages,
transfusions, surgeries, ongoing pregnancies, or any other complication
except death.116 This change conveniently obscured any ability to trace the
impact of the other changes the FDA made to the use of mifepristone, such
as the expansion of use from forty-nine to seventy days gestation and the
allowance of abortion providers to not check to ensure the complete passage
of tissue (a completed abortion).117
In 2017, Graham Chelius, an individual provider, sued the FDA
demanding the removal of REMS from mifepristone as violative of the
Administrative Procedures Act (APA) and the Fifth Amendment to the U.S.
Constitution.118 In 2020, the American College of Obstetricians &
Gynecologists (ACOG)119 also sued the FDA demanding the removal of the
REMS entirely from mifepristone, this time under the guise of COVID-19.
However, abortion advocates had been working for years prior to the
COVID-19 pandemic to completely de-medicalize mifepristone, with the
end goal being over-the-counter access to mifepristone.120 This would
eliminate the “obstacle” of conscientious objection by healthcare
professionals and effectively nullify many laws regulating abortion
throughout the United States.
Drugs with REMS cannot be sold over-the-counter. Elimination of the
REMS would allow mifepristone and misoprostol to be sold over-thecounter.121 In October 2020, the Supreme Court suspended an injunction by
115

Aultman et al., supra note 12, at 23–24.
Id.
117
Id. at 6–7.
118
Complaint at 9, 62, Chelius v. Wright, No. 1:17-cv-00493 (D. Haw. Oct. 3, 2017).
119
Complaint at 2–4, Am. Coll. of Obstetricians & Gynecologists v. FDA, No. 8:20-cv01320 (D. Md. May 27, 2020).
120
See, e.g., Univ. Cal. S.F., Over-the-Counter Medication Abortion, ANSIRH,
www.ansirh.org/research/ongoing/over-counter-medication-abortion (last visited Jan. 29,
2022); Renee B. Sherman & Daniel Grossman, The FDA Didn’t Liberate Abortion—But We
Still Can, NATION (Dec. 17, 2021), https://www.thenation.com/article/society/fda-abortionpill/; Carrie N. Baker, FDA Lifts Some Abortion Pill Restrictions, Leaves Others in Place, MS.
MAG. (Dec. 17, 2021), https://msmagazine.com/2021/12/17/fda-abortion-pill-medicationbiden-mifepristone/; R. Alta Charo, A Political History of RU-486, in BIOMEDICAL POLITICS 48
(Kathi E. Hanna ed., 1991) (“The drug offers the prospect of performing abortions in any
physician’s office and even at home. The prospect of eliminating abortion clinics . . . has
made feminists enthusiastic supporters of the drug.”).
121
Frequently Asked Questions (FAQs) About REMS, FDA,
https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/frequently116

398

LIBERTY UNIVERSITY LAW REVIEW

[Vol. 16:3

a federal district court and left in place the part of the REMS requiring inperson administration of mifepristone by a physician.122 However, after the
Biden Administration took office, the FDA suspended the requirement in
December 2021.123
In summary, the FDA’s approval of mifepristone was fraught with
irregularities including: the accelerated approval under Subpart H which was
intended solely for drugs that treat “serious or life-threatening conditions”;
the inexplicable waiver of the Pediatric Rule which requires testing in the
population of women under 18; the unprecedented requirement of Cytotec
as part of the abortion regiment despite the objections of the manufacturer;
and the unlawful waiver of the two blinded, controlled trials requirement.
After approval, the FDA failed to enforce post-marketing restrictions despite
the fact that abortion providers began violating those restrictions within
weeks of approval and after the off-label vaginal use of the second drug,
misoprostol, resulted in the deaths of women from a deadly infection. The
FDA continued to relax restrictions on mifepristone use without any reliable
mechanism of verifying either complications or deaths. In fact, by removing
the adverse event reporting requirement for prescribers in 2016, the FDA
guaranteed that data on adverse events would not be collected or reported.124
Then, in 2021, the FDA made the unprecedented decision to no longer
require that a woman be examined by a competent medical professional
before being given mifepristone.125 That in-person exam is the only
opportunity to rule out an ectopic (outside the uterus) pregnancy.126 An inperson exam is also necessary to accurately determine gestational age,
administer Rhogam for women with Rh negative blood types, and to screen
for coercion and abuse. The FDA has abandoned its responsibility to
minimize the risks to women from chemical abortion.
III. THE LIMITS OF FEDERAL APPROVAL & OVERSIGHT OF CHEMICAL
ABORTION
A.

Abortion in a Post-Roe World

asked-questions-faqs-about-rems (Jan. 26, 2018) (“REMS do not apply to over-the-counter
(OTC) medications.”).
122
FDA v. Am. Coll. of Obstetricians & Gynecologists, 141 S. Ct. 578, 578 (2021).
123
Letter from Patrizia Cavazzoni to Graham Chelius, supra note 13.
124
Aultman et al., supra note 12, at 6–7.
125
See id.
126
Mifepristone is contraindicated for ectopic pregnancy; it cannot treat an ectopic
pregnancy and may mask the symptoms, leading to the risk of life-threatening
complications. Aultman et al., supra note 12, at 21–22; see also House Subcommittee Staff
Report, supra note 58, at 4–5.
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The Supreme Court’s decision in 2021 to hear the case of Dobbs v. Jackson
Women’s Health Organization,127 a direct challenge to Roe v. Wade, will likely
spur abortion advocates to accelerate their drive toward complete demedicalization of mifepristone. There are more than seventy websites where
a woman can order abortion pills without any physician involvement.128 In
2021, the FDA replied to the Chelius and ACOG suits by announcing that
the FDA would no longer enforce the in-person requirement, thereby
allowing the distribution of abortion drugs by mail.129
The implications of the FDA deciding to relax its requirements are
significant. The average American woman will now not know the risks of this
drug. If she has a complication, it will not be tracked, analyzed, or
anonymously reported to public health agencies. Complications will
certainly occur, and increase, because women can now use the drug at
advanced gestational ages. This also has serious implications for the risk of
coerced abortion. Currently, there is no meaningful or effective way to
prevent bad actors like disgruntled boyfriends, pimps, sex traffickers, or
abusers from ordering mifepristone.130 Women and girls forced into sex
trafficking, and those who choose to work as prostitutes, may experience
forced abortion. The risk for coerced abortion using online abortifacient
drugs is significant.131
But the implications do not end there. If the complication rate increases
from DIY abortions, it may be attributed to state limits on abortion, rather
127

Dobbs v. Jackson Women’s Health Org., 141 S. Ct. 2619, 2619–20 (2021).
Fact Sheet: Online Sales of Mifeprex and Misoprostol for Self-Abortion, CHARLOTTE
LOZIER INST. (Apr. 23, 2018), https://lozierinstitute.org/fact-sheet-online-sales-of-mifeprexand-misoprostol-for-self-abortion/.
129
Letter from Janet Woodcock, M.D., Acting Comm’r Food & Drugs, U.S. Food & Drug
Admin., to Maureen G. Phipps, M.D., CEO, Am. Coll. of Obstetricians & Gynecologists &
William Grobman, M.D., President, Soc’y Maternal-Fetal Med. (Apr. 12, 2021),
https://www.aclu.org/sites/default/files/field_document/fda_acting_commissioner_letter_to
_acog_april_12_2021.pdf; see also Letter from Patrizia Cavazzoni to Graham Chelius, supra
note 13; Kate Smith, Biden Administration to Lift Abortion Pill Restriction Amid Pandemic,
CBS NEWS (April 13, 2021, 11:30 AM), https://www.cbsnews.com/news/abortion-pillrestrictions-lifted-pandemic-fda/ (quoting statement by ACOG CEO Maureen G. Phipps
that “the in-person dispensing requirement for mifepristone is unnecessary and restrictive”).
130
AM. ASS’N OF PRO-LIFE OBSTETRICIANS & GYNECOLOGIST & AM. COLL. OF
PEDIATRICIANS, JOINT COMMITTEE OPINION PORNOGRAPHY, SEX TRAFFICKING AND ABORTION
1, 8 (2019) [hereinafter JOINT COMMITTEE OPINION]; see generally Catherine T. Coyle et al.,
The Relationship of Abortion and Violence Against Women: Violence Prevention Strategies
and Research Needs, 30 ISSUES L. & MED. 111, 114–15, 117 (2015).
131
See JOINT COMMITTEE OPINION, supra note 130, at 8. See generally Coyle et al., supra
note 130, at 114–15, 117. Some states prohibit coerced abortion. See, e.g., IDAHO CODE § 18615 (2022) (prohibiting coerced abortion); WIS. STAT. § 253.10(3)(b), (3)(c) (2021).
128
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than the increase in DIY abortions.132 The challenge to state legislators, law
enforcement, and public health officials will be obvious.
B.

Lack of Adequate Abortion Data Collection Analysis & Reporting in
the U.S.

The FDA approved RU-486 for the U.S. medical market without any reliable
national system of abortion data collection, reporting, and analysis. The
Supreme Court issued Roe in 1973 without such a reliable system in the U.S.,
and none exists today. There is no federal law mandating the collection and
reporting of abortion data from states or abortion providers. The Supreme
Court invalidated state reporting laws in Thornburgh v. American College of
Obstetricians and Gynecologists.133 Only two organizations in the U.S. collect
and report national abortion data, and the collection and reporting from both
is terribly flawed and incomplete. The Guttmacher Institute is a private,
abortion-advocacy organization, which collects data directly from abortion
providers, but that reporting is voluntary. Only 40%–50% of clinics report
data in any given year.134 The U.S. Centers for Disease Control and
Prevention (CDC) collects data from the states; that reporting is also
voluntary, and not all states report their data.135 California is the most
significant state that has not reported its abortion data to the CDC in many
years. Since “nearly a quarter” of all induced abortions in the U.S. are done
in California, “much of the data regarding induced abortion is entirely
immune to analysis.”136 The voluntary and inconsistent nature of abortion
reporting from the states makes the CDC’s annual report incomplete at best
and skewed by selective reporting at worst. Consequently, the annual number
of abortions reported by the CDC is merely an estimate. The annual number

132
See, e.g., ROBIN MARTY, NEW HANDBOOK FOR A POST-ROE AMERICA 153 (2nd ed. 2021)
(“What to Know About Self-Managed Abortion Care with Abortion Pills and/or Herbs”);
Baker, supra note 120; Amelia Butterly et al., 100 Women: The Modern Face of the ‘DIY
Abortion’, BBC (June 6, 2018), https://www.bbc.com/news/world-44089526.
133
Thornburgh v. Am. Coll. of Obstetricians & Gynecologists, 476 U.S. 747, 765–68
(1986) (invalidating § 3214 and § 3211 of Pennsylvania’s reporting requirements), overruled
by Planned Parenthood of Se. Pa. v. Casey, 505 U.S. 833 (1992).
134
Rachel K. Jones et al., Abortion in the United States: Incidence and Access to Services,
2005, 40 PERSP. ON SEXUAL & REPROD. HEALTH 6, 7, 15–16 (2008) (collecting data from
responses to mailed questionnaires and recognizing limitations of failing to identify certain
abortion providers and other abortion providers failing to respond or submitting incomplete
responses).
135
See Burk Schaible, Improving the Accuracy of Maternal Mortality and Pregnancy
Related Death, 29 ISSUES L. & MED. 231, 232 (2014).
136
Schaible, supra note 135, at 232.
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of abortions reported by the CDC and the AGI differs by 15% or more.137
Americans cannot reliably know the annual number of abortions, nor the
number or rate of complications for surgical or chemical abortions.
In addition, accurate abortion collection and reporting is necessary to
accurately compare maternal death from abortion with death from childbirth,
but this “remains an impossible task given the current limitations within the
CDC Abortion Mortality Surveillance System and [the World Health
Organization’s] International Statistical Classification of Diseases and Related
Health Problems (ICD).”138 Unfortunately, “[t]hese systems lack a systematic
and comprehensive method of collecting complete records regarding abortion
outcomes in each state,” and “the ICD-10 classification does not identify the
most proximal causes of death related to induced abortion.”139 The CDC admits
that reporting abortion-related deaths is “not federally mandated.”140 Thus, no
valid comparison can be made between deaths from abortion and deaths from
childbirth, making the common claim that “abortion is safer than childbirth”
scientifically unsupportable.141
Consequently, there is an inability to reliably track abortion complications in
the United States. Because there is no reliable national number of abortions, but
rather, simply estimates, there is no reliable national number or rate of
complications. Thus, women cannot receive accurate data on complication
rates, and it is doubtful that they are ever informed about the lack of reliable
data. Without accurate data on the risks of an abortion procedure, patients
cannot be fully informed or truly give informed consent.142 Data also are
137
See Karen Pazol et al., Abortion Surveillance—United States, 2008, CTRS. FOR DISEASE
CONTROL & PREVENTION MORBIDITY & MORTALITY WKLY. REP.: SURVEILLANCE SUMMARIES,
Nov. 25, 2011, at 1, 10.
138
Id.; see also WORLD HEALTH ORG., 2 ICD-10: INTERNATIONAL STATISTICAL
CLASSIFICATION OF DISEASES AND RELATED HEALTH PROBLEMS 99 (10th rev. 2d ed. 2004),
https://apps.who.int/iris/bitstream/handle/10665/42980/9241546530_eng.pdf?sequence=1&i
sAllowed=y.
139
Schaible, supra note 135, at 238–39.
140
Tara C. Jatlaoui et al., Abortion Surveillance—United States, 2016, CTRS. DISEASE
CONTROL & PREVENTION MORBIDITY & MORTALITY WKLY. REP.: SURVEILLANCE SUMMARIES,
Nov. 29, 2019, at 1, 37 tbl.17.
141
See Schaible, supra note 135, at 232; Clarke D. Forsythe & Bradley N. Kehr, A Road
Map Through the Supreme Court’s Back Alley, 57 VILL. L. REV. 45, 60–62 (2012) (comparing
the published abortion mortality rate and the childbirth mortality rate); Brief for the
American Center for Law and Justice et al. as Amici Curiae Supporting Petitioner at *27,
Gonzales v. Planned Parenthood Fed’n of Am., 547 U.S. 1205 (2006) (No. 05-1382), 2006
U.S. S. Ct. Briefs LEXIS 613.
142
See Clarke D. Forsythe & Rachel N. Morrison, Stare Decisis, Workability, and Roe v.
Wade: An Introduction, 18 AVE MARIA L. REV. 48, 77–85 (2020) (providing a more detailed
analysis of this problem).
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unavailable or incomplete because of the number of patients who fail to return
for follow-up examinations.143 The lack of completed patient follow-up visits
impedes accurate reporting of latent complications and adverse events.
Finally, the FDA administers an FDA Adverse Event Reporting System
(FAERS) that covers mifepristone abortions, though it too is seriously
compromised in its efficacy and accuracy.144 The FAERS system detects only a
small proportion of adverse events that actually occur, as documented in a
recent publication by Cirucci, Aultman, and Harrison:
There is also concern that the FDA will continue to rely on the
FAERS to make decisions about removing mifepristone
REMS, despite the findings herein that FAERS does not
include all the events even known to the abortion provider. To
compound this problem, in 2016, the FDA eliminated the
requirement to report adverse events resulting from
mifepristone other than death. Nevertheless, in her April 12,
2021[,] letter to the American College of Obstetricians and
Gynecologists, FDA Commissioner Janet Woodcock stated
that, based on a review of post-marketing AEs from January
27, 2020, to January 12, 2021, the in-person dispensing
requirements in the mifepristone REMS would not be
enforced. It is alarming that policy decisions that affect
women’s safety are based on a lack of information in the
FAERS. Whether the inaccuracy of FAERS extends to required
reporting for other medications is unknown to us, but the
findings in this paper have significant implications for drug
safety evaluation in general.145
The FDA requires manufacturers and doctors to follow the REMS in their
provision of mifepristone and misoprostol.146 The FDA emphasized that “[i]n

143

Aultman et al., supra note 12, at 22–24.
See id. at 8–10, 22–24; Christina A. Cirucci et al., Mifepristone Adverse Events
Identified by Planned Parenthood in 2009 and 2010 Compared to Those in the FDA Adverse
Event Reporting System and Those Obtained Through the Freedom of Information Act, 8
HEALTH SERVS. RSCH. & MANAGERIAL EPIDEMIOLOGY 1, 1 (2021).
145
Cirucci et al., supra note 144, at 3 (footnotes omitted).
146
U.S. FOOD & DRUG ADMIN., RISK EVALUATION AND MITIGATION STRATEGY (REMS)
SINGLE SHARED SYSTEM FOR MIFEPRISTONE 200MG (Apr. 2019),
https://www.accessdata.fda.gov/drugsatfda_docs/rems/mifepristone_2019_04_11_REMS_D
ocument.pdf.
144
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some cases[,] very heavy vaginal bleeding will need to be stopped by a surgical
procedure, which can often be performed in a healthcare provider’s office.”147
Contrast the U.S. with other nations. For example, Scandinavian countries
have a national registry that thoroughly records abortions and collects,
analyzes, and reports data for public health purposes.148 They have more
reliable data because they pay for and track abortions. They have a registry that
the U.S. lacks.149 Those nations have better abortion data recording and stronger
safety controls on distribution and administration of RU-486. In France, in
1992, the process of administering RU-486 involved four visits with a
physician.150 France also required a “one week [] reflection” period and carefully
controlled distribution.151
For these reasons, international data may be more reliable than domestic
data in assessing the risks of mifepristone and misoprostol. A 2009 study found
that chemical abortion had higher complication rates than surgical abortion.152
There are numerous international, peer-reviewed studies of women finding an
increased risk of preterm birth after abortion,153 an increased risk of mental
trauma after abortion,154 and an increased risk of breast cancer after abortion.155
There is also evidence of an increased risk of preterm birth in the one out of five
women who require a surgical completion after chemical abortion.156
147
Questions and Answers on Mifeprex, FDA, https://www.fda.gov/drugs/postmarketdrug-safety-information-patients-and-providers/questions-and-answers-mifeprex (Dec. 16,
2021).
148
Schaible, supra note 135, at 232–33 (citing countries).
149
Id.
150
Baulieu, supra note 59, at 154.
151
Id.
152
Maarit Niinimäki et al., Immediate Complications After Medical Compared with
Surgical Termination of Pregnancy, 114 OBSTETRICS & GYNECOLOGY 795, 795 (2009).
153
Practice Guideline 11: A Detailed Examination of the Data on Surgical Abortion and
Preterm Birth, AM. ASS’N PRO-LIFE OBSTETRICIANS & GYNECOLOGISTS, Nov. 2021, at 1, 1,
https://aaplog.org/wp-content/uploads/2021/11/PG-11-A-Detailed-Examination-of-theData-on-Surgical-Abortion-and-Preterm-Birth.pdf.
154
Practice Bulletin 7: Abortion and Mental Health, AM. ASS’N PRO-LIFE OBSTETRICIANS &
GYNECOLOGISTS, Dec. 30, 2019, at 1, 1, https://aaplog.org/wpcontent/uploads/2019/12/FINAL-Abortion-Mental-Health-PB7.pdf.
155
Pro. Ethics Comm. AAPLOG, Committee Opinion 8: Abortion and Breast Cancer, AM.
ASS’N PRO-LIFE OBSTETRICIANS & GYNECOLOGISTS (Jan. 5, 2020), https://aaplog.org/wpcontent/uploads/2020/01/FINAL-CO-8-Abortion-Breast-Cancer-1.9.20.pdf.
156
Hua Liao et al., Repeated Medical Abortions and the Risk of Preterm Birth in the
Subsequent Pregnancy, 284 ARCHIVES GYNECOLOGY & OBSTETRICS 579, 583–84 (2011)
(“Overall, 20.3% of the patients in the medical cohort received a postabortion suction
curettage. . . . Compared to women without postabortion curettage, women with a history of
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Women who take mifepristone also need to know whether they are Rh
negative. If a woman is Rh negative, the ACOG recommends an injection of Rh
immunoglobulin (brand name, RhoGAM) at the time of the abortion.157 This is
an international medical standard: “After miscarriage or threatened abortion
or induced abortion during the first 12 weeks of gestation, non-sensitized Dnegative women should be given a minimum anti-D of 120 µg. After 12
weeks’ gestation, they should be given 300 µg. (II-3B).”158 If a physician does
not administer RhoGAM, Rh negative women may experience Rh
incompatibility in future pregnancies, which could create a significant risk of
complications and miscarriages.159 Therefore, a qualified doctor must
determine blood type and provide RhoGAM if a woman is Rh negative.160
RhoGAM cannot be adequately administered in a mail-order system for
chemical abortion. Neither DIY, nor mail-order abortions will provide
informed consent and follow-up care which doctors could provide.
IV. THE NEED FOR STATE REGULATION
A.

The Importance of State Regulation

Because of the inherent risks of mifepristone and misoprostol, the
weaknesses of the FAERS system, the FDA’s decision to relax the REMS, and
the lack of any reliable national system of abortion data, the U.S. has a national
medical climate that does not adequately protect women’s health when it comes
to abortion. These inadequacies are compounded by the FDA’s refusal to track
medical complications of abortion.161
Some states may prohibit chemical abortion if Dobbs v. Jackson Women’s
Health Organization overturns Roe v. Wade and the abortion issue is returned
to the states, because of the states’ traditional protection of the life of prenatal
human beings. Other states, such as California, Illinois, and New York, will

MA earlier than 7 completed weeks and postabortion curettage were at an increased risk of
PTB (OR 1.69, 95% CI 1.02–3.16); and the risk was even higher for very PTB (OR 3.61, 95%
CI 1.43–4.93) (Table 4)”).
157
Robert M. Silver & Am. Coll. of Obstetricians and Gynecologists, Practice Bulletin 181:
Prevention of Rh D Alloimmunization, 130 OBSTETRICS & GYNECOLOGY e57, e62–e63 (2017)
[hereinafter Practice Bulletin No. 181].
158
Karen Fung Kee Fung & Erica Eason, Prevention of Rh Alloimmunization, 25 J.
OBSTETRICS & GYNAECOLOGY CAN. 765, 766 (2003).
159
See Practice Bulletin No. 181, supra note 157, at e58, e65.
160
Id. at e61.
161
AM. ASS’N PRO-LIFE OBSTETRICIANS & GYNECOLOGISTS, COMMITTEE OPINION 6:
INDUCED ABORTION AND THE INCREASED RISK OF MATERNAL MORTALITY 5 (2019),
https://aaplog.org/wp-content/uploads/2019/08/AAPLOG-CO-6-Induced-Abortion-andthe-Increased-Risk-of-Maternal-Mortality.pdf.
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undoubtedly allow abortion for the foreseeable future. These states have a
compelling interest in independently regulating chemical abortion to protect
women’s health and ensure fully informed consent.
The lack of state and federal regulation puts the burden on women to obtain
fully informed consent. Women cannot be fully informed without an accurate
understanding of the risks. States should act to ensure that women are fully
informed by requiring medical oversight and accurate medical data.
During the FDA’s evaluation of RU-486 and before its approval, more than
a dozen states had introduced legislation to regulate RU-486.162 To adequately
protect women’s health and guard against the documented risks, states should
require (1) in-person screening for risk factors for adverse mental health
outcomes including screening for sex trafficking and coercion; (2) intra-uterine
pregnancy verification by ultrasound; (3) fully-informed consent by the patient;
(4) identification of blood type to rule out Rh negativity; (5) in-person
administration of mifepristone by a physician in order to ensure that the patient
is the actual recipient of the drug and that the drug is not surreptitiously
administered to another person; (6) administration only by a physician who is
credentialed and has admitting privileges or has made written arrangements
with another physician to manage expected complications; (7) a second followup visit with a doctor to confirm a completed abortion; (8) a third in-person
visit to ensure complete expulsion and rule out retained tissue; (9) gestational
limits on the use of mifepristone and misoprostol; (10) adequate documentation
of the fulfillment of all requirements; and (11) that essential medical data is
reported for public health analysis.
Since the FDA approved RU-486 in 2000, a number of states have acted to
partially fill the vacuum and regulate chemical abortion consistent with the
medical risks and in light of the minimal FDA regulations. Nearly half the states

162

Stephanie Simon, Abortion Rights Group Challenges Mich. Law, L.A. TIMES (Feb. 27,
2001, 12:00 AM), https://www.latimes.com/archives/la-xpm-2001-feb-27-mn-30745story.html (“16 states have introduced legislation to restrict the use of RU-486.”).
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now regulate chemical abortion specifically.163 More considered chemical
abortion regulations in the 2022 state legislative sessions.164
At least twelve states that regulate chemical abortion require physicians to
inform their patients about the established medical process of reversing

163
ALA. STAT. § 26-23E-7 (2021) (requiring a physician to prescribe abortion-inducing
drugs); ARIZ. REV. STAT. § 36-2153 (2021); ARIZ. REV. STAT. § 36-2160 (2021) (requiring inperson distribution of abortion-inducing drugs prescribed by a physician); ARK. CODE
ANN. § 20-16-1504 (2021) (detailing physician requirements before prescribing an abortioninducing drug and requiring in-person distribution of abortion-inducing drugs); IDAHO
CODE § 18-617 (2021) (regulating chemical abortions); IND. CODE ANN. § 16-34-2-1 (2021)
(criminalizing abortion unless certain circumstances are present); 410 IND. ADMIN. CODE
26.5-1-1 (2022); IOWA CODE § 144.29A (2021) (reporting requirement); IOWA ADMIN. CODE
r. 653-13.10 (2022) (outlining standards of practice for physicians who administer abortioninducing drugs); KAN. STAT. ANN. § 65-4a10 (2021) (requiring the physician to be physically
present when mifepristone is administered); KY. REV. STAT. ANN. § 311.728 (LexisNexis
2021) (requiring the physician to be physically present when an abortion is induced or
performed); KY. REV. STAT. ANN. § 311.774 (LexisNexis 2021) (reporting requirements); LA.
STAT. ANN. § 40:1061 (2021); MISS. CODE ANN. § 41-41-107 (2021) (requirements for
physicians); MO. REV. STAT. § 188.021 (2021) (requirements for administering abortioninducing drugs); MONT. CODE ANN. § 50-20-704 (2021) (requiring a physician to be
physically present when abortion-inducing drugs are administered); MONT. CODE ANN. § 5020-705 (2021) (requirements for distributing abortion-inducing drugs); NEB. REV. STAT.
ANN. § 28-335 (2021) (requiring a licensed physician to be physically present when an
abortion is induced or performed); N.D. CENT. CODE § 14-02.1-03.5 (2021) (requiring a
physician to prescribe and administer an abortion-inducing drug); OHIO REV. CODE
ANN. § 2919.123 (LexisNexis 2022); OHIO REV. CODE ANN. § 2919.124 (LexisNexis 2022)
(requiring a physician to be physically present when an abortion-inducing drug is
consumed); OKLA. STAT. tit. 63, §§ 1-756.1–1-756.11 (2021) (“Oklahoma Abortion-Inducing
Drug Risk Protocol Act”); S.C. CODE ANN. § 44-41-460 (2021) (reporting requirements); S.D.
CODIFIED LAWS § 34-23A-10.1 (2021) (requiring informed consent); S.D. Exec. Order 202112 (Sept. 7, 2021); TENN. CODE ANN. § 39-15-218 (2021) (requiring physician to provide
information about reversal); TEX. HEALTH & SAFETY CODE ANN. §§ 171.061–171.065 (2021);
UTAH CODE ANN. §§ 76-7-305–76-7-305.5 (LexisNexis 2021) (requiring informed consent
including the consequences of medication-induced abortion and the option to consult
doctor about mifepristone reversal); W. VA. CODE ANN. §§ 16-2I-2–16-2I-3 (2021); WIS.
STAT. § 253.105 (2022) (requiring a physical exam and a physician’s physical presence when
abortion-inducing drug is administered).
164
See, e.g., Nicole Ki, South Dakota Gov. Kristi Noem Announces Proposal to Ban Most
Abortions in the State, USA TODAY (Jan. 23, 2022, 3:34 PM),
https://www.usatoday.com/story/news/nation/2022/01/23/south-dakota-kristi-noemabortion-ban/6630393001/; Elizabeth Nash et al., 2022 State Legislative Sessions: Abortion
Bans and Restrictions on Medication Abortion Dominate, GUTTMACHER INST. (Mar. 16, 2022),
https://www.guttmacher.org/article/2022/03/2022-state-legislative-sessions-abortion-bansand-restrictions-medicationabortion?utm_source=Guttmacher+Email+Alerts&utm_campaign=b77de93c8babortionsbansandmedicationabortions&utm_medium=email&utm_term=0_9ac83dc920b77de93c8b-260729057.
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progesterone with administration of natural progesterone.165 This reversal
process is based both on understanding the basic pharmacology of
mifepristone as well as animal studies and human retrospective studies.
Mifepristone works by blocking a natural pregnancy hormone called
progesterone.166 Progesterone is produced by the mother’s body to allow her
womb to grow the placenta167—the organ needed to provide nourishment to
the baby.168 Mifepristone blocks progesterone’s actions in a woman’s
uterus.169 When mifepristone blocks progesterone, the placenta deteriorates
and can no longer provide nourishment to the baby.170 During the
development of mifepristone, researchers clearly demonstrated that
mifepristone is a reversible blocker of progesterone.171 Thus, if a woman’s
progesterone is blocked with mifepristone, and then, within a limited time
period, a physician administers more progesterone, the mifepristone
blockade may be overcome, and the effects of mifepristone nullified.172 By
giving a woman progesterone, the mifepristone abortion can be stopped and
the chances of the baby surviving increase from 25% (the survival rate
without natural progesterone) to 68% (the best protocol survival rate after
giving natural progesterone).173 This is a significantly increased chance of the
baby surviving the attempted chemical abortion after mifepristone. For a
165

ARK. CODE ANN. §§ 20-16-1703 to 20-16-1704 (2021); IND. CODE ANN. §§ 16-34-2-1,
16-34-2-1.1(2021); KY. REV. STAT. ANN. § 311.774 (LexisNexis 2021); LA. STAT.
ANN. § 40:1061 (2021); MONT. CODE ANN. § 50-20-708 (2021); NEB. REV. STAT. ANN. § 28327.01 (2021); N.D. CENT. CODE § 14-02.1-02.1 (2021); OKLA. STAT. ANN. tit. 63, § 1-756.7
(2021); S.D. CODIFIED LAWS § 34-23A-10.1 (2021); TENN. CODE ANN. § 39-15-218 (2021);
UTAH CODE ANN. § 76-7-305.5 (LexisNexis 2021); W. VA. CODE ANN. § 16-2I-2 (2022). The
laws of Oklahoma and North Dakota are not currently in effect. See Tulsa Women’s
Reproductive Clinic v. Hunter [D and E ban], REWIRE NEWS GRP.,
https://rewirenewsgroup.com/legislative-tracker/legal-case/tulsa-womens-reproductiveclinic-v-hunter-d-and-e-ban/ (last updated Nov. 4, 2019); Am. Med. Ass’n v. Stenhjem, 412
F. Supp. 3d 1134, 1138, 1152 (D.N.D. 2019) (granting preliminary injunction).
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See supra notes 58–63 and accompanying text.
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Gracy Rosario et al., Role of Progesterone in Structural and Biomedical Remodeling of
Endometrium, 8 FRONTIERS BIOSCIENCE 924, 925–26 (2003).
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Graham J. Burton & Eric Jauniaux, What is the Placenta?, AM. J. OBSTETRICS &
GYNECOLOGY, Oct. 2015, at S6, S6.
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Davenport et al., supra note 69, at 6.
170
Id.
171
Id. at 5–6.
172
Practice Bulletin 6: The Reversal of the Effects of Mifepristone by Progesterone, AM.
ASS’N PRO-LIFE OBSTETRICIANS & GYNECOLOGISTS, Nov. 16, 2019, at 1, 2-3 [hereinafter
Practice Bulletin 6], https://aaplog.org/wp-content/uploads/2020/01/FINAL-PB-6-AbortionPill-Reversal-1.pdf.
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Id. at 4.
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woman who changes her mind after starting a chemical abortion, the
administration of progesterone can give her real hope of saving her unborn
child.
IVF practitioners have used progesterone for over forty years to help
women carry pregnancies after embryo implantation into the womb.174 There
is a very long and solid history of safety with the use of natural progesterone
in pregnancy.175 Natural progesterone use in pregnancy for the last fifty years
has not been associated with any increased risk of birth defects.176 The use of
mifepristone without the use of misoprostol has not demonstrated an
increased risk of birth defects that would advise against the use of
progesterone to reverse the effects of mifepristone before misoprostol is
taken in the two-drug regimen.177 Thus, to date, there does not appear to be
any significant risk of birth defects in the unborn child from abortion pill
reversal.178 Moreover, abortion pill reversal offers another reproductive
choice for women facing the abortion decision.
To adequately protect women’s health in the context of chemical abortion,
there are numerous facets that must be addressed. At least nineteen states
require a physician’s physical presence when abortion-inducing drugs are

174

Walter Ciampaglia & Graciela E. Cognigni, Clinical Use of Progesterone in Infertility
and Assisted Reproduction, 94 ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA 17, 19
(2015).
175
The Prac. Comm. of the Am. Soc’y of Reprod. Med., Progesterone Supplementation
During the Luteal Phase and in Early Pregnancy in the Treatment of Infertility: An
Educational Bulletin, 89 FERTILITY & STERILITY 789, 789, 791 (2008). “The weight of available
evidence indicates that the most common forms of P supplementation during early
pregnancy pose no significant risk to mother and fetus” and “[c]ontrolled studies show no
increase in congenital anomalies, including genital abnormalities in male and female infants,
resulting from maternal exposure to P . . . during early pregnancy.” Id. at 791.
176
Delgado et al., supra note 62, at 26.
177
Practice Bulletin 6, supra note 172, at 4.
178
Delgado et al., supra note 62, at 26.
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administered.179 Approximately thirty-three states require that only physicians
may administer abortions.180
States set standards for informed consent in numerous areas of health and
medicine.181 State requirements for the anonymous reporting of abortion data
is critical for public health, for accurate understanding of complications, and for
fully informed consent about the safety of medical procedures. This is necessary
to prevent complications from being filtered out of the public health system. For

179
These include Alabama (ALA. CODE § 26-23E-7 (2021)), Arizona (ARIZ. REV.
STAT. § 36-2160 (2021)), Arkansas (ARK. CODE ANN. § 20-16-1504 (2021)), Indiana (IND.
CODE ANN. § 16-34-2-1 (LexisNexis 2021)), Iowa (IOWA ADMIN. CODE r. 653.13-10 (2022))
(requiring physician to perform a physical exam before mifepristone abortion, be physically
present when providing abortion, and schedule follow-up appointment) (enjoined by court
See Planned Parenthood v. Iowa Bd. of Med., 865 N.W.2d 252, 269 (Iowa 2015)), Kentucky
(KY. REV. STAT. ANN. § 311.728 (LexisNexis 2021)), Louisiana (LA. STAT. ANN. § 40:1061.11
(2021)), Mississippi (MISS. CODE ANN. § 41-41-107 (2021)), Missouri (MO. REV.
STAT. § 188.021 (2021)), Nebraska (NEB. REV. STAT. ANN. § 28-335 (2021)), North Carolina
(N.C. GEN. STAT. § 90-21.82 (2021)), North Dakota (N.D. CENT. CODE § 14-02.1-03.5 (2021)),
Oklahoma (OKLA. STAT. tit. 63, § 1-756.3 (2021)), South Carolina (see S.C. CODE ANN. § 4441-20 (2022)), South Dakota (S.D. Exec. Order 2021-12 (Sept. 7, 2021)), Tennessee, Texas
(TEX. HEALTH & SAFETY CODE ANN. § 171.063 (West 2021)), West Virginia, Wisconsin (WIS.
STAT. § 253.105 (2022)).
180
These include Alabama (ALA. CODE § 26-23E-7 (LexisNexis 2021)), Alaska (ALASKA
STAT. § 18.16.010 (2021), Arizona (ARIZ. REV. STAT. § 36-2160 (2021)), Arkansas (ARK. CODE
ANN. § 20-16-1504 (2021)), Delaware (DEL. CODE ANN. tit. 24, § 1790 (2022)), Florida (FLA.
STAT. ANN. § 390.0111 (LexisNexis 2021)), Georgia (GA. CODE ANN. § 16-12-141 (2021)),
Idaho (IDAHO CODE § 18-608A (2022)), Indiana (IND. CODE ANN. § 16-34-2-1 (2021)), Iowa,
Kansas (KAN. STAT. ANN. § 65-4a10 (2021)), Kentucky (KY. REV. STAT. ANN. § 311.728
(LexisNexis 2021)), Louisiana (LA. STAT. ANN. § 40:1061.10 (2021)), Maryland (MD. CODE
ANN. HEALTH-GENERAL § 20-208 (LexisNexis 2021)), Michigan, Minnesota (MINN.
STAT. § 145.412 (2022)), Mississippi (MISS. CODE ANN. § 41-41-107 (2022)), Missouri (MO.
REV. STAT. § 188.020 (2021)), Nebraska (NEB. REV. STAT. ANN. § 28-335 (2022)), Nevada
(NEB. REV. STAT. ANN. § 442.250 (2021)), North Carolina (N.C. GEN. STAT. § 14-45.1 (2021)),
North Dakota (N.D. CENT. CODE § 14-02.1-04 (2021)), Ohio (OHIO REV. CODE
ANN. § 2929.123 (LexisNexis 2022)), Oklahoma (OKLA. STAT. ANN. tit. 63, § 1-756.3 (2021)),
Pennsylvania, South Carolina (S.C. CODE ANN. § 44-41-20 (2022)), South Dakota (S.D.
CODIFIED LAWS § 34-23A-3 (2022)), Tennessee (TENN. CODE. ANN. § 63-6-241 (2021)), Texas
(TEX. HEALTH & SAFETY CODE ANN. § 170A.002 (West 2021)), Utah (UTAH CODE ANN. § 767-302 (LexisNexis 2021)), West Virginia, Wisconsin (WIS. STAT. § 940.15 (2022)), and
Wyoming (WYO. STAT. ANN. § 35-6-11 (2021)).
181
See, e.g., Marc D. Ginsberg, Informed Consent: No Longer Just What the Doctor
Ordered? Revisited, 52 AKRON L. REV. 49 (2018); Alicia Ouellette, Body Modification and
Adolescent Decision Making: Proceed with Caution, 15 J. HEALTH CARE L. & POL’Y 129 (2012);
A.D. Burnett III, Comment, Suturing the Loophole: Informed Consent as a Requirement for
Procedures Not Enumerated in Pennsylvania’s Medical Informed Consent Statute, 108 PENN.
STATE L. REV. 1249 (2004); Maria Woltjen, Regulation of Informed Consent to Human
Experimentation, 17 LOY. U. L.J. 507 (1986).
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example, Arkansas enacted an abortion complications reporting law in 2019.182
During 2020, the state found that of the forty-five complication reports filed in
2020, forty (88%) of them resulted from chemical abortion.183
States have expressed concern with the risks of hemorrhage, severe infection,
and temporary or permanent loss of fertility from chemical abortion.184 States
have also been concerned with the need to rule out an ectopic (outside the
uterus) pregnancy,185 since RU-486 is contraindicated in the case of an ectopic
pregnancy.186 If a woman has an ectopic pregnancy there are risks that RU-486
will not effectively end the pregnancy, the ectopic pregnancy could rupture, or
the woman could suffer a severe, life-threatening hemorrhage.187 In addition,
there is a need for states to step in to ensure providers are following the health
and safety regulations that they previously ignored.188
However, states have not completely filled the vacuum left by the lack of
federal regulations. No state requires the tracking of the sale and delivery of
chemical abortion. Severe infection complications—like sepsis from ectopic
pregnancy and emergency surgery—should all be tracked. Pharmaceutical
protocols could also protect women’s health. States also have the authority to
restrict mail-order abortions. Texas and other states prohibit mail-order
abortion.189
States have good reason to second-guess the courts on the safety of abortion.
For example, in Planned Parenthood v. Danforth, the Supreme Court struck
down a Missouri law prohibiting the use of saline abortion on the rationale
182

ARK. CODE ANN. § 20-16-605 (West 2021) (effective July 24, 2019).
CTR. OF HEALTH STATISTICS, ARK. DEP’T OF HEALTH, INDUCED ABORTIONS
COMPLICATIONS REPORT: REQUIRED BY ACT 620 OF 2019,
https://www.healthy.arkansas.gov/images/uploads/pdf/complication_final_2020.pdf (last
visited Mar. 3, 2022).
184
See 2012 Ariz. Sess. Laws 250; 2017 Idaho Sess. Laws 242; OKLA. STAT. tit. 63, § 1729-a
(2021).
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See 2012 Ariz. Sess. Laws 250; 2017 Idaho Sess. Laws 242; OKLA. STAT. tit. 63, § 1729-a
(2021).
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Sabina Parveen et al., Rupture Ectopic Pregnancy in Early Gestation Due to
Mifepristone & Misoprostol Abuse, 5 INT’L J. MED. RSCH. PROS. 218, 220 (2019).
187
Id.
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Some abortion clinics prescribe mifepristone up to fourteen weeks, beyond the
original forty-nine days and beyond the current FDA-approved deadline of ten weeks
(seventy days). Women’s Center of Tampa: Medical & Surgical Abortion Clinic, ORLANDO
WOMEN’S CTR., https://www.womenscenter.com/womens_center_hyde_park.html (last
visited Mar. 4, 2022). The same clinic advertises in-patient mifepristone abortion up to
twenty-four weeks gestation. Id.
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Besides Texas (TEX. HEALTH & SAFETY CODE ANN. § 171.063 (West 2021)), these
include Louisiana (LA. STAT. ANN. § 40:1061.11 (2021)), and Mississippi (MISS. CODE
ANN. § 41-41-107 (2022)).
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that that would take away a widely used method of abortion.190 However, the
prohibition of saline as an abortifacient could have induced providers to use
an alternative that was less risky to women. As it turned out and was apparent
to some at the time, saline was not a good method and was soon succeeded
by alternatives.191 The Supreme Court in City of Akron v. Akron Center for
Reproductive Health, expressly affirmed that “[o]f course, the State retains an
interest in ensuring the validity of Roe’s factual assumption that ‘the first
trimester abortion [is] as safe for the woman as normal childbirth at term.’”192
States have good reason to limit the gestational weeks in which
mifepristone and misoprostol can be used and to require in-person
administration by a physician, pregnancy verification, the use of ultrasound
to rule out an ectopic pregnancy, and gestational verification by ultrasound.
In addition, states are justified in adopting requirements to identify if Rh
negativity is present, to require an in-person follow up visit; to verify fetal
remains; to require fully informed consent with a sufficient reflection period;
and to require that abortion data be recorded and reported for public health
examination.
Although federal preemption of state regulations of mifepristone may be
litigated, there is a presumption in favor of state police powers over public
health and the practice of medicine.193 As Justice Stevens wrote for the Supreme
Court in Wyeth v. Levine, “we start with the assumption that the historic police
powers of the States were not to be superseded by the Federal Act unless that
was the clear and manifest purpose of Congress.”194 Since colonial days, states
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Planned Parenthood of Cent. Mo. v. Danforth, 428 U.S. 52, 75–79 (1976).
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193
See generally Elizabeth Y. McCuskey, Body of Preemption: Health Law Traditions and
the Presumption against Preemption, 89 TEMP. L. REV. 95 (2016).
194
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have restricted or prohibited abortion.195 Recognizing the diversity of abortion
mechanisms, states have traditionally identified and prohibited various
mechanisms, including medicines, drugs, and other abortifacients.196 There is
no federal statute approving mifepristone, let alone one that clearly preempts
state regulations. The Supreme Court recently affirmed in National Federation
of Independent Business v. Department of Labor, that “[a]dministrative agencies
are creatures of statute. They accordingly possess only the authority that
Congress has provided.”197 The Court affirmed that “[w]e expect Congress to
speak clearly when authorizing an agency to exercise powers of vast
economic and political significance.”198 The FDA’s expertise extends to
determining whether a drug is safe and effective.199 Whether the use of a drug is
good public policy traditionally falls within the states’ police powers.200 Finally,
there is good reason to believe that Congress has limited constitutional power
over abortion.201 For all these reasons, the traditional presumption favoring
state regulation of medicine and medical practice is especially strong in the case
195

See DELLAPENNA, supra note 1, at 211–28.
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of an elective abortion, which does not treat disease or any life-threatening
condition.202
V. CONCLUSION
The inherent risks of mifepristone and misoprostol combined with the
failure of adequate federal governmental oversight over the approval of
chemical abortion in the U.S. over the past quarter-century means that state
abortion policy may come full circle. Just as states in the nineteenth and
twentieth centuries sought to prohibit dangerous abortion methods to protect
the lives and health of women and children,203 states need to now prevent DIY
and mail-order abortions using mifepristone and misoprostol in order to
prevent significant health risks to women and to protect the lives of prenatal
human beings. Effective regulations will require that women receive full
information about the risks of chemical abortion and give fully informed
consent; that providers are qualified and able to adequately address any medical
complications; that mifepristone-misoprostol is only administered with
medical supervision; that emergency medical care is available; that public health
data is comprehensively collected, analyzed, and reported in their state; and that
these laws are effectively enforced.
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